Drug news
NICE approves Xtandi (Astellas/Medivation) for Prostate Cancer
NICE has recommended that Xtandi (enzalutamidea), from Astellas and Medivation, for Prostate Cancer should be used on the state health service. The draft guidance is conditional on Xtandi being provided at an undisclosed discount and only for use in patients whose disease has progressed during or after docetaxel-containing chemotherapy. Xtandi is is designed to treat advanced Prostate Cancer in patients who have previously received chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.